Literature DB >> 33922344

Ductal Dilatation of ≥5 mm in Intraductal Papillary Mucinous Neoplasm Should Trigger the Consideration for Pancreatectomy: A Meta-Analysis and Systematic Review of Resected Cases.

Y H Andrew Wu1, Atsushi Oba1,2, Laurel Beaty1,3, Kathryn L Colborn1,3,4, Salvador Rodriguez Franco1,5, Ben Harnke6, Cheryl Meguid1, Daniel Negrini1,7, Roberto Valente1,8, Steven Ahrendt1,9, Richard D Schulick1,9, Marco Del Chiaro1,9.   

Abstract

Intraductal papillary mucinous neoplasms (IPMN) are common but difficult to manage since accurate tools for diagnosing malignancy are unavailable. This study tests the diagnostic value of the main pancreatic duct (MPD) diameter for detecting IPMN malignancy using a meta-analysis of published data of resected IPMNs. Collected from a comprehensive literature search, the articles included in this analysis must report malignancy cases (high-grade dysplasia (HGD) and invasive carcinoma (IC)) and MPD diameter so that two MPD cut-offs could be created. The sensitivity, specificity, and odds ratios of the two cutoffs for predicting malignancy were calculated. A review of 1493 articles yielded 20 retrospective studies with 3982 resected cases. A cutoff of ≥5 mm is more sensitive than the ≥10 mm cutoff and has pooled sensitivity of 72.20% and 75.60% for classification of HGD and IC, respectively. Both MPD cutoffs of ≥5 mm and ≥10 mm were associated with malignancy (OR = 4.36 (95% CI: 2.82, 6.75) vs. OR = 3.18 (95% CI: 2.25, 4.49), respectively). The odds of HGD and IC for patients with MPD ≥5 mm were 5.66 (95% CI: 3.02, 10.62) and 7.40 (95% CI: 4.95, 11.06), respectively. OR of HGD and IC for MPD ≥10 mm cutoff were 4.36 (95% CI: 3.20, 5.93) and 4.75 (95% CI: 2.39, 9.45), respectively. IPMN with MPD of >5 mm could very likely be malignant. In selected IPMN patients, pancreatectomy should be considered when MPD is >5 mm.

Entities:  

Keywords:  high grade dysplasia; intraductal papillary mucinous neoplasm; invasive carcinoma; meta-analysis; pancreatic cancer; pancreatic cystic neoplasm; pancreatic main duct dilatation

Year:  2021        PMID: 33922344     DOI: 10.3390/cancers13092031

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  56 in total

Review 1.  Intraductal papillary mucinous neoplasms of the pancreas: reporting clinically relevant features.

Authors:  Marco Del Chiaro; Caroline Verbeke
Journal:  Histopathology       Date:  2017-01-15       Impact factor: 5.087

2.  Nonoperative management of main pancreatic duct-involved intraductal papillary mucinous neoplasm might be indicated in select patients.

Authors:  Alexandra M Roch; John M DeWitt; Mohammad A Al-Haddad; Christian M Schmidt; Eugene P Ceppa; Michael G House; Nicholas J Zyromski; Attila Nakeeb; C Maximillian Schmidt
Journal:  J Am Coll Surg       Date:  2014-03-19       Impact factor: 6.113

3.  How to perform a meta-analysis with R: a practical tutorial.

Authors:  Sara Balduzzi; Gerta Rücker; Guido Schwarzer
Journal:  Evid Based Ment Health       Date:  2019-09-28

4.  Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a population-based study.

Authors:  Marie-Luise Kromrey; Robin Bülow; Jenny Hübner; Christin Paperlein; Markus M Lerch; Till Ittermann; Henry Völzke; Julia Mayerle; Jens-Peter Kühn
Journal:  Gut       Date:  2017-09-06       Impact factor: 23.059

5.  Active Surveillance Beyond 5 Years Is Required for Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms Undergoing Non-Operative Management.

Authors:  Stefano Crippa; Raffaele Pezzilli; Massimiliano Bissolati; Gabriele Capurso; Luigi Romano; Maria Paola Brunori; Lucia Calculli; Domenico Tamburrino; Alessandra Piccioli; Giacomo Ruffo; Gianfranco Delle Fave; Massimo Falconi
Journal:  Am J Gastroenterol       Date:  2017-02-28       Impact factor: 10.864

Review 6.  Nature and management of pancreatic mucinous cystic neoplasm (MCN): A systematic review of the literature.

Authors:  Linda N Nilsson; Margaret G Keane; Awad Shamali; Judith Millastre Bocos; Monica Marijinissen van Zanten; Anne Antila; Cristina Verdejo Gil; Marco Del Chiaro; Johanna Laukkarinen
Journal:  Pancreatology       Date:  2016-09-20       Impact factor: 3.996

7.  Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma.

Authors:  Sang Myung Woo; Ji Kon Ryu; Sang Hyub Lee; Ji Won Yoo; Joo Kyung Park; Yong-Tae Kim; Yong Bum Yoon
Journal:  Pancreas       Date:  2008-01       Impact factor: 3.327

8.  Single-operator pancreatoscopy is helpful in the evaluation of suspected intraductal papillary mucinous neoplasms (IPMN).

Authors:  Urban Arnelo; Antti Siiki; Fredrik Swahn; Ralf Segersvärd; Lars Enochsson; Marco del Chiaro; Lars Lundell; Caroline S Verbeke; J-Matthias Löhr
Journal:  Pancreatology       Date:  2014-09-27       Impact factor: 3.996

9.  The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).

Authors:  Matthew T McMillan; Russell S Lewis; Jeffrey A Drebin; Ursina R Teitelbaum; Major K Lee; Robert E Roses; Douglas L Fraker; Charles M Vollmer
Journal:  Cancer       Date:  2015-11-20       Impact factor: 6.860

10.  Occurrence of the potent mutagens 2- nitrobenzanthrone and 3-nitrobenzanthrone in fine airborne particles.

Authors:  Aldenor G Santos; Gisele O da Rocha; Jailson B de Andrade
Journal:  Sci Rep       Date:  2019-01-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.